Redefining the therapeutic objective in psoriatic patients candidates for biological therapy

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Burudpakdee C, Gala S, et al. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014;14:685–705.
   PubMed Web of Science ®Google Scholar
• Hawro T, Zalewska A, Hawro M, et al. Impact of psoriasis severity on family income and quality of life. J Eur Acad Dermatol Venereol. 2015;29:438–443.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Shi L, et al. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21:874–888.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, de Jong EMGJ, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28:438–453.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149:1180–1185.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871–781.
   PubMed Web of Science ®Google Scholar
• Callis Duffin K, Yeung H, Takeshita J, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2014;170:672–680.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Nast A, et al. Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting. J Eur Acad Dermatol Venereol. 2011;25(Suppl 3):1–13. doi:10.1111/j.1468-3083.2011.04033.x
   PubMedGoogle Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–1199.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Thaci D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173:777–787.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–417.
   PubMed Web of Science ®Google Scholar
• de Villiers MR, de Villiers PJ, Kent AP. The Delphi technique in health sciences education research. Med Teach. 2005;27:639–643.
   PubMed Web of Science ®Google Scholar
• Fitch K, Bernstein SJ, Aguilar MD, et al. (2001). The RAND/UCLA Appropriateness Method User’s Manual. (RAND).
   Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• van Lumig PP, van de Kerkhof PC, Boezeman JB, et al. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients. J Eur Acad Dermatol Venereol. 2013;27:593–600.
   PubMed Web of Science ®Google Scholar
• Armesto S, Coto-Segura P, Mayorga J, et al. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: a retrospective study of 100 patients in daily practice. J Dermatolog Treat. 2015;26:49–53.
   PubMed Web of Science ®Google Scholar
• Hagg D, Sundstrom A, Eriksson M, et al. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J Eur Acad Dermatol Venereol. 2015;29:452–456.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013;69:385–392.
   PubMed Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:1183–1190.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81:44–52.
   PubMed Web of Science ®Google Scholar
• Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369–375.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Parsi K, Schupp CW, et al. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol. 2013;149:577–582.
   PubMed Web of Science ®Google Scholar
• Youn SW, Choi CW, Kim BR, et al. Reduction of Inter-Rater and Intra-Rater Variability in Psoriasis Area and Severity Index Assessment by photographic training. Ann Dermatol. 2015;27:557–562.
   PubMed Web of Science ®Google Scholar
• Fernandez-Torres RM, Paradela S, Fonseca E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatolog Treat. 2014;25:54–56.
   PubMed Web of Science ®Google Scholar
• Moreno-Ramirez D, Ojeda-Vila T, Ferrandiz L. Disease control for patients with psoriasis receiving continuous versus interrupted therapy with adalimumab or etanercept: a clinical practice study. Am J Clin Dermatol. 2014;15:543–549.
   PubMed Web of Science ®Google Scholar
• Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69:931–937.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659–664.
   PubMed Web of Science ®Google Scholar
• Twiss J, Meads DM, Preston EP, et al. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol. 2012;132:76–84.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Blauvelt A, Sofen HL, et al. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol. 2013;12:874–880.
   PubMed Web of Science ®Google Scholar
• Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333–337.
   PubMed Web of Science ®Google Scholar
• Torii H, Sato N, Yoshinari T, et al. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39:253–259.
   PubMed Web of Science ®Google Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29:645–648.
   PubMed Web of Science ®Google Scholar
• Zhu B, Edson-Heredia E, Guo J, et al. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol. 2014;171:1215–1219.
   PubMed Web of Science ®Google Scholar
• Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92:497–501.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502–507.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Kromer C, Herr R, et al. Treatment satisfaction of patients with psoriasis. Acta Derm Venereol. 2015;95:572–578.
   PubMed Web of Science ®Google Scholar
• Ribera M, Daudén E, Puig L, et al. Design and validation of a questionnaire to measure treatment satisfaction in patients with moderate-to-severe psoriasis: the NEODERMA study. Actas Dermo-Sifiliograficas. 2011;102:28–38.
   PubMedGoogle Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L. Treatment goals for psoriasis: Should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015;106:155–157.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23–31.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60–69.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412–421.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, phase III clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;76:AB112.
   Google Scholar
• Lafuente-Urrez RF, Perez-Pelegay J. Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice. Eur J Dermatol. 2014;24:217–223.
   PubMed Web of Science ®Google Scholar
• Inzinger M, Heschl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol. 2011;165:640–645.
   PubMed Web of Science ®Google Scholar
• Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172:1371–1383.
   PubMed Web of Science ®Google Scholar
• Paul C, Puig L, Kragballe K, et al. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Br J Dermatol. 2014;170:425–434.
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Paul C, et al. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol. 2014;170:435–444.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Szepietowski JC, Sigurgeirsson B, etet al. Secukinumab maintains reductions in PASI through second year of treatment: A randomized extension of the ERASURE and FIXTURE studies in plaque psoriasis. J Am Acad Dermatol. 2016;74:AB271.
   Web of Science ®Google Scholar
• Gourraud PA, Le Gall C, Puzenat E, et al. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol. 2012;132:2171–2175.
   PubMed Web of Science ®Google Scholar
• Zweegers J, Roosenboom B, van de Kerkhof PC, et al. Frequency of and predictors for a high clinical response in psoriasis patients on biologic therapy in daily practice. Br J Dermatol. 2017;176:786–793.
   PubMed Web of Science ®Google Scholar
• Shear NH, Hartmann M, Toledo-Bahena ME, et al. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice. Qual Life Res. 2016;25:2031–2040.
   PubMed Web of Science ®Google Scholar
• Couto MI, Carneiro S, Niemeyer-Corbellini JP, et al. Correlation Between Severity Index and Quality of Life Index in patients with psoriasis assessed before and after phototherapy. Skinmed. 2016;14:93–97.
   PubMedGoogle Scholar
• Chaptini C, Quinn S, Marshman G. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study. Australas J Dermatol. 2015;57:72–75.
   Web of Science ®Google Scholar
• Heredi E, Rencz F, Balogh O, etet al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ. 2014;15 (Suppl 1): S111–S119.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Sterry W, Brock F, et al. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. Br J Dermatol. 2015;172:230–238.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Griffiths CE, Lebwohl M, et al. Reaching complete or near complete resolution of psoriasis: benefit and risk considerations. Br J Dermatol. 2017;177:587–590.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Puig L, Mordin M, etet al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Treat. 2017;28:492–499.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71:633–641.
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26:235–239.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Armstrong AW. Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. Sem Cutan Med Surg. 2014;33:91–97.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:694–709.
   PubMedGoogle Scholar
• Carrascosa JM, Belinchon I, de-la-Cueva P, et al. Expert recommendations on treating psoriasis in special circumstances. Actas Dermosifiliogr. 2015;106:292–309.
   PubMed Web of Science ®Google Scholar
• Romero-Jimenez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, et al. Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol. J Dermatolog Treat. 2016;27:198–202.
   PubMed Web of Science ®Google Scholar
• Baniandres O, Rodriguez-Soria VJ, Romero-Jimenez RM, et al. Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting. Actas Dermosifiliogr. 2015;106:569–577.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Garcia-Doval I, Perez-Zafrilla B, et al. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26:502–506.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167:658–667.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36.
   PubMed Web of Science ®Google Scholar
• Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28:390–403.
   PubMed Web of Science ®Google Scholar
• Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009;23:1394–1397.
   PubMed Web of Science ®Google Scholar
• Van Lumig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol. 2010;163:838–846.
   PubMed Web of Science ®Google Scholar
• Ayala F, Lambert J. Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: a multicenter, open-label trial (TANGO). J Dermatolog Treat. 2015;26:304–311.
   PubMed Web of Science ®Google Scholar
• Papp KA, Barber K, Bissonnette R, et al. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). J Eur Acad Dermatol Venereol. 2015;29:361–366.
   PubMed Web of Science ®Google Scholar
• Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163:402–411.
   PubMed Web of Science ®Google Scholar
• Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012;166:147–153.
   PubMed Web of Science ®Google Scholar
• Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012;23:261–267.
   PubMed Web of Science ®Google Scholar
• Lucas A, Belinchon I, Perez-Crespo M, et al. Successful response to narrow-band UVB in a patient undergoing concomitant treatment with adalimumab for psoriasis. Australas J Dermatol. 2008;49:173–174.
   PubMed Web of Science ®Google Scholar
• Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed. 2011;27:186–189.
   PubMed Web of Science ®Google Scholar
• Belinchon I, Arribas MP, Soro P, et al. Recovery of the response to biological treatments using narrow band ultraviolet-B in patients with moderate to severe psoriasis: a retrospective study of 17 patients. Photodermatol Photoimmunol Photomed. 2014;30:316–322.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Carmichael AJ, et al. Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol. 2009;34:415–416.
   PubMed Web of Science ®Google Scholar
• Driessen RJ, Boezeman JB, van de Kerkhof PC, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol. 2009;160:670–675.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167:649–657.
   PubMed Web of Science ®Google Scholar
• Puig L. Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. J Eur Acad Dermatol Venereol. 2013;27:257–260.
   Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in Patients with Psoriasis. N Engl J Med. 2003;349:2014–2022.
   PubMed Web of Science ®Google Scholar
• Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24:169–178.
   PubMed Web of Science ®Google Scholar
• Maria Fernandez-Torres R, Paradela S, Fonseca E. Long-term efficacy of etanercept for plaque-type psoriasis and estimated cost in daily clinical practice. Value Health. 2015;18:1158–1161.
   PubMed Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165:1109–1117.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566.
   PubMed Web of Science ®Google Scholar
• Molina-Leyva A, Husein-Elahmed H, Naranjo-Sintes R, et al. Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting. J Drugs Dermatol. 2014;13:971–974.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
   PubMed Web of Science ®Google Scholar
• van den Reek JM, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135:1.
   PubMed Web of Science ®Google Scholar
• Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68:64–72.
   PubMed Web of Science ®Google Scholar
• Vilarrasa E, Notario J, Bordas X, et al. ORBIT (outcome and retention rate of biologic treatments for psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74:1066–1072.
   PubMed Web of Science ®Google Scholar
• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32:983–1028.
   PubMed Web of Science ®Google Scholar
• Esposito M, Gisondi P, Cassano N, et al. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis. Drug Dev Res. 2014;75 (Suppl 1): S31–S34.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164:1091–1096.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172:244–252.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135:2632–2640.
   PubMed Web of Science ®Google Scholar
• Cao Z, Carter C, Wilson KL, et al. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2015;26:113–120.
   PubMed Web of Science ®Google Scholar
• Ross C, Marshman G, Grillo M, et al. Biological therapies for psoriasis: adherence and outcome analysis from a clinical perspective. Australas J Dermatol. 2016;57:137–140.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nobeyama Y, Hayashi M, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40:1008–1013.
   PubMed Web of Science ®Google Scholar
• Zweegers J, van den Reek JM, van de Kerkhof PC, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175:340–347.
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Sangiorgi D, Perrone V, et al. Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. Clinicoecon Outcomes Res. 2014;6:401–407.
   PubMedGoogle Scholar
• Menting SP, Sitaram AS, Stok HMB, et al. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014;171:875–883.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148–1158.
   PubMed Web of Science ®Google Scholar
• Davila-Seijo P, Dauden E, Carretero G, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30:1942–1950.
   PubMed Web of Science ®Google Scholar
• Lopez-Ferrer A, Vilarrasa E, Gich IJ, et al. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169:1141–1147.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–411.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)). Br J Dermatol. 2015;173:1387–1399.
   PubMed Web of Science ®Google Scholar